Introduction
============

Despite improvements in therapy, heart failure (HF) remains a leading cause of morbidity and mortality, affecting more than 37 million people worldwide and conferring a substantial burden on the health-care system [@B1]. It has been demonstrated that HF is associated with a pro-inflammatory state, mainly through an increase in pro-inflammatory adipokines and a decrease in anti-inflammatory adipokines, regulated by the expression of thermogenic genes [@B2]. Epicardial Adipose Tissue (EAT) has been proposed to participate in this adipokines production dysbalance and energy homeostasis, contributing to the pathogenesis of HF [@B3], but has not been fully characterized.

The main aim of our study was to assess the expression of thermogenic genes (Uncoupling protein 1 (UCP1), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) and PR-domain-missing 16 (PRDM16) in EAT in patients with HF, stablishing the difference between patients with reduced ejection fraction (HFr-EF) and preserved ejection fraction (HFp-EF) and to evaluate the association with clinical and biochemical variables.

Material and Methods
====================

Patients
--------

Patients with HF who underwent elective cardiac surgery (coronary artery bypass and/or valve replacement) were included in our study and divided according to left ventricular ejection fraction (LVEF) determined by left ventriculography. HFr-EF was defined as an EF ≤40%, whereas HFp-EF was defined as an EF \>40%. Exclusion criteria were severe infections, acute inflammatory diseases and/or cancer. Data about demographics and clinical characteristics, and biochemical parameters were collected.

The study was approved by the Institutional Research Ethics Committee from Hospital Universitario Virgen de la Victoria (Málaga, Spain) and carried out in accordance with the Declaration of Helsinki. Only patients who had previously given written informed consent were enrolled in this study.

Biological material
-------------------

EAT biopsy samples (0.2-0.5g) were obtained near the proximal right coronary artery 1 hour after anesthesia. All the tissues were immediately frozen in liquid nitrogen and stored at -80ºC for RNA isolation.

In addition, peripheral venous blood was obtained and drawn into pyrogen-free tubes with or without ethylenedianminetetraacetic acid (anticoagulant). For serum, the tubes were left at room temperature for 20 min and then centrifuged at 1500 g for 10 min at 4ºC. In the hospital laboratory, fasting glucose, glycated hemoglobin (HbA1c), total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, creatinine, uric acid, glutamic-oxolacetic transaminase (GOT), glutamate-piruvate transaminase (GPT), gamma-glutamyl transferase (GGT), C-reactive protein (CRP), calcium, sodium and potassium were measured in a Dimension autoanalyzer (Dade Behring Inc., Deerfield, IL) by enzymatic methods (Randox Laboratories, Ldt., UK).

The gene expression levels in the adipose tissue were determined by real time quantitative polymerase chain reaction (PCR) using a predesigned and validated Taqman primer/probe sets.

Statistical analysis
--------------------

Continuous variables are summarized as mean ± standard deviation with Student\'s T test used to test the significance of between-group differences. Discrete variables are presented as frequencies and percentages with between-group differences tested using Pearson chi-square test. Multiple regression analysis were used in order to identify independent predictors of EAT UCP1, PGC1α and PRDM16 levels, as well as to control for confounding factors; and those clinical variables that achieved P\<0.05 on between-group comparison and cardiovascular plausible variables were included in the model. Logistic regression analysis was used to define the risk factors of reduced LVEF, and odds ratio (OR) and 95% Confidence Interval (95%CI) were calculated. SPSS for Windows version 15 (SPSS Inc. Chicago, IL, USA) was used for analyses and values were considered significant at P\<0.05.

Results
-------

Among the 75 patients in our study, 42.7% (n=32) had reduced LVEF. Clinical and laboratory differences between patients with reduced and preserved LVEF HF are listed in Table [1](#T1){ref-type="table"}. Among patients with reduced LVEF, there were more men and more likely to have coronary artery disease and obesity, and less valve heart disease.

UCP1, PGC1α and PRDM16 mRNA in EAT were significantly lower in patients with reduced LVEF (P=0.004, P=0.002 and P=0.02, respectively) (Figure [1](#F1){ref-type="fig"}).

Multiple regression analysis showed that age, male gender, body max index (BMI), presence of obesity, type-2-diabetes mellitus (DM2), hypertension and coronary artery disease and LVEF were independently associated with EAT UCP1, PGC1α, and PRDM16 mRNA levels (Table [2](#T2){ref-type="table"}).

Thermogenic genes expressions in EAT were showed as protective factors against the presence of HFr-EF, and age, presence of coronary artery disease and type-2-diabetes mellitus were associated as risk factor in the logistic regression analysis (Table [3](#T3){ref-type="table"}).

Discussion
==========

The present study found that patients with HFr-EF expressed significantly lower thermogenic genes (UCP1, PGC1α and PRDM16) in EAT than those with HFpEF. Age, male gender and different cardiovascular diseases were associated with the levels of thermogenic genes expression. EAT UCP1, PGC1α and PRDM16 mRNA levels were shown as possible protective factors against HFr-EF, and age and presence of CAD and DM2 were shown as risk factors.

These findings are important because they support the hypothesis that EAT thermogenic function could play an important role in the pathogenesis of HF. This is one of very few studies that have explored the influence of EAT on heart function in patients with HF and this is unique in that it assessed the association between thermogenic genes expression and HFr-EF and HFp-EF.

EAT represents a visceral brown-like adipose tissue located between the myocardium and the inner layer of visceral pericardium with a close anatomical proximity to the myocardium [@B4]. A functional EAT has been proposed to play a protector role over the myocardium but in pathological situations may be implicated in the development and/or progression of heart disease [@B3]-[@B5]. Several studies have shown that EAT is associated with the pathogenesis of HF, but focusing on EAT volume determined by echocardiography, magnetic resonance or computed tomography. Increased EAT thickness has been related to the severity of HF and explored the influence on diastolic and systolic functions [@B6],[@B7]. However, only limited studies have explored the functionality of EAT [@B2],[@B8]. Recent investigations have assessed the relationship between EAT gene expression in patients with HF, finding a functional role of EAT in the regulation of the development of HF [@B8]. p53, a tumor suppressor that coordinates DNA repair, cell cycle arrest and apoptosis; and adiponectin, an important anti-inflammatory adipokine, have been the principal gene expressions suggested to be important mediators of HF progression [@B9].

A number of reports have investigated the association between thermogenic gene expression such as UCP1, PGC1α and PRDM16, and coronary artery disease and other cardiovascular risk factors [@B10]. These genes have been recognized as specific marker of brown adipocites and regulators of oxidative metabolism and mitochondrial biogenesis, playing a relevant role in cardiac status [@B2]. A decrease of their gene mRNA expressions in EAT in patients with HFr-EF suggests a loss of EAT brown-like features, promoting pro-inflammatory and atherosclerotic pathways, exposing the heart to an excessive toxicity [@B11]. In line with these finding, we showed the thermogenic function of EAT and its involvement in the LVEF.

We acknowledge the following limitations in this study. We recruited a small number of recruited patients; our data were from a single hospital; and only small EAT biopsy samples were taken, being insufficient for a proteins determination. However, our study was carried out using a well-designed protocol and well-stablished methods. The hypothesis that EAT thermogenic genes expression was involved in patients with HF and influenced according to LVEF would need to be confirmed in a larger and multicenter research study.

In conclusion, the expression of thermogenic genes (UCP1, PGC1α and PRDM16) was lower in patients with HFr-EF than in those with HFp-EF. These genes have been shown as possible protective factors against HFr-EF, suggesting a loss of functional EAT brown-like features, what, subsequently, would participate in a deleterious manner on heart metabolism. Thermogenic genes could represent a future novel therapeutic target in patients with HFr-EF.

The authors thank the cardiac surgeons from Department of Heart Surgery (Virgen de la Vitoria Hospital, Málaga) for their contribution in collecting samples.

###### 

UCP1 (A), PGC1α(B) and PRDM16 (C) mRNA expression in EAT comparison between groups. Values are shown as mean ± standard deviation. Values were considered to be statistically significant when P\<0.05. EAT: epicardial adipose tissue; HFp-EF: heart failure preserved-ejection fraction; HFr-EF: heart failure reduced ejection fraction; PGC1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PRDM16: PR-domain-missing 16; UCP1: uncoupling protein 1
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###### 

Clinical and laboratory characteristics of patients with heart failure with reduced and preserved left ventricular ejection fraction

  ----------------------------------------------------------------------
  Variables\                     HFr-EF\        HFp-EF\        P value
  N (%)                          (n=32)         (n=43)         
  ------------------------------ -------------- -------------- ---------
  Age, years                     62.5 ± 10.3    62.8 ± 11.5    0.718

  Male gender                    26 (81.3)      28 (65.1)      0.003

  Body mass index, kg/m^2^       26.6 ± 4.4     29.4 ± 5.3     0.03

  LVEF, %                        34.9 ± 3.9     60.4 ± 8.5     \<0.001

  Cardiovascular risk factors                                  

  Current smoking                14 (43.8)      16 (37.2)      0.267

  Dyslipidemia                   15 (46.9)      23(53.5)       0.317

  Hypertension                   17 (53.1)      25 (58.1)      0.296

  Diabetes mellitus              10 (31.3)      16 (37.2)      0.277

  Obesity                        14 (43.8)      21 (48.8)      0.127

  Coronary artery disease        19 (59.4)      17 (39.5)      0.04

  Multivessel coronary disease   22 (68.8)      30 (69.8)      0.431

  Valve heart disease            15 (46.9)      28 (65.1)      0.03

  Cerebrovascular disease        3 (9.4)        3 (7)          0.442

  Medications                                                  

  Aspirin                        17 (53.1)      24 (55.8)      0.766

  Statin                         14 (43.8)      22 (51.2)      0.104

  ACEI/ARB                       19 (59.4)      25 (58.1)      0.425

  Beta-blocker                   21 (65.6)      31 (72.1)      0.370

  Biochemical data                                             

  Glucose, mg/dL                 129.8 ± 57.7   122.1 ± 43.7   0.349

  HbA1c, %                       6.6 ± 1.3      6.2 ± 1.3      0.721

  Total cholesterol, mg/dL       160± 36        163± 42        0.395

  LDL cholesterol, mg/dL         97± 39         98± 33         0.381

  HDL cholesterol, mg/dL         40± 8.5        39 ± 14        0.320

  Triglycerides, mg/dL           161± 53        144± 61        0.197

  Creatinine, mg/dL              1.3± 0.8       1 ± 0.4        0.711

  Uric acid, mg/dL               6.7± 3.6       5.6± 1.9       0.07

  GOT, IU/L                      28.9± 11.9     35.3 ± 37      0.112

  GPT, IU/L                      33.9± 18.9     36.9± 29.1     0.426

  GGT, IU/L                      61.6± 44.8     52.1± 57.6     0.479

  CRP, mg/dL                     27.1± 46.6     17± 32.9       0.222

  Calcium, mg/dL                 8.5 ± 0.7      8.5± 0.8       0.858

  Potassium, mmol/L              4.2± 0.7       4.3± 0.4       0.855

  Sodium, mmol/L                 136± 4.4       138± 3.5       0.342
  ----------------------------------------------------------------------

Values are shown as mean ± standard deviation and frequencies (percentages).

Values were considered to be statistically significant when P\<0.05.

ACEI: Angiotensin Converting Enzyme Inhibitor; ARB: Antiotensin II Receptro Blocker; CRP: C-Reactive Protein; GGT: Gamma-Glutamyl Transferase; GOT: Glutamic-Oxolacetic Transaminase; GPT: Glutamate-Piruvate Transaminase; Hb1ac: glycated hemoglobin; HDL: High-Density Lipoprotein; HFp-EF: heart failure with preserved ejection fraction; HFr-EF: heart failure with reduce ejection fraction; IU/L: international units/liter; kg/m^2^: kilogram/square metre; LDL: Low-Density Lipoprotein; LVEF: left ventricular ejection fraction; mg/dL: milligram/deciliter;mmol/L: milimol/liter

###### 

Multiple regression analysis for prediction of epicardial adipose tissue UCP1, PGC1α and PRDM16 mRNA levels

  Variables                 EAT UCP1 mRNA (R^2^=0.503)   EAT PGC1α mRNA (R^2^=0.641)   EAT PRDM16 mRNA (R^2^=0.499)                                                                 
  ------------------------- ---------------------------- ----------------------------- ------------------------------ -------- ----------------- ------- -------- ----------------- -------
  Age                       0.071                        0.019-0.132                   0.032                          0.099    0.032-0.199       0.003   0.079    0.041-0.177       0.041
  Gender (Man)              0.119                        -0.043-(-0.291)               0.040                          -0.152   -0.064-(-0.237)   0.001   -0.101   -0.041-(-0.301)   0.041
  Body mass index           -0.090                       -0.002-(-0.301)               0.041                          -0.181   -0.001-(-0.248)   0.039   -0.088   -0.012-(-0.431)   0.049
  Obesity                   -0.281                       -0.108-(-0.931)               0.029                          -0.381   -0.119-(-0.849)   0.022   -0.229   -0.099-(-0.983)   0.041
  Diabetes Mellitus         -0.230                       -0.101-(-0.931)               0.041                          -0.460   -0.159-(-0.869)   0.044   -0.201   -0.032-(-0.899)   0.044
  Hypertension              0.083                        0.021-0.333                   0.044                          0.131    0.021-0.343       0.039   0.072    0.012-0.435       0.049
  Dyslipidemia              0.145                        -0.241-2.001                  0.519                          0.243    -0.343-1.141      0.439   0.198    -0.341-1.191      0.321
  Coronary artery Disease   -0.111                       -0.003-(-0.801)               0.041                          -0.098   -0.003-(-0.798)   0.038   -0.131   -0.003-(-0.813)   0.044
  LVEF                      0.222                        0.081-0.344                   0.002                          0.399    0.049-0.598       0.001   0.119    0.052-0.301       0.002

Values were considered to be statistically significant when P \< 0.05

CI: Confidence Interval; EAT: epicardial adipose tissue; LVEF: left ventricular ejection fraction; PGC1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PRDM16: PR-domain-missing 16; UCP1: uncoupling protein 1.

###### 

Logistic regression analysis for the presence of heart failure with reduced ejection fraction

  Variable                  OR (95% CI)            P value
  ------------------------- ---------------------- ---------
  UCP1 mRNA                 0.617 (0.103-0.989)    0.042
  PGC1α mRNA                0.416 (0.171-0.912)    0.031
  PRMD16 mRNA               0.643 (0.116-0.997)    0.044
  Age                       1.643 (1.001-3.143)    0.026
  Gender (man)              7.867 (0.717-26.101)   0.223
  Body mass index           2.341 (0.683-8.033)    0.312
  Obesity                   3.001 (0.843-12.301)   0.323
  Diabetes mellitus         4.031 (1.099-7.231)    \<0.001
  Hypertension              2.499 (0.798-14.133)   0.492
  Dyslipidemia              3.301 (0.639-9.103)    0.329
  Coronary artery disease   6.743 (1.932-15.301)   \<0.001

Values were considered to be statistically significant when P\<0.05.

CI: confidence Interval; OR: odds ratio; PGC1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PRDM16: PR-domain-missing 16; UCP1: uncoupling protein 1.
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